Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | NAAA | Q02083 | 3/20 | 0.49 |
| ▸ | PPARG | P37231 | 3/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11593166 | 0.98 | NAAA (0.51) | EPHX2ALDH1A1NAAAPPARGEPHX1 | |
| SCHEMBL2059827 | 0.98 | NAAA (0.51) | EPHX2ALDH1A1NAAAPPARGEPHX1 | |
| SCHEMBL6049453 | 0.98 | NAAA (0.51) | EPHX2ALDH1A1NAAAPPARGEPHX1 | |
| SCHEMBL30977763 | 0.98 | NAAA (0.51) | EPHX2ALDH1A1NAAAPPARGEPHX1 | |
| SCHEMBL21569213 | 0.98 | NAAA (0.51) | EPHX2ALDH1A1NAAAPPARGEPHX1 | |
| SCHEMBL5710073 | 0.98 | NAAA (0.51) | EPHX2ALDH1A1NAAAPPARGEPHX1 | |
| SCHEMBL26846117 | 0.98 | NAAA (0.51) | EPHX2ALDH1A1NAAAPPARGEPHX1 | |
| SCHEMBL3294299 | 0.98 | EPHX2 (0.49) | EPHX2ALDH1A1NAAAPPARGPRKCA | |
| SCHEMBL20994218 | 0.98 | EPHX2 (0.51) | EPHX2ALDH1A1NAAAPPARGEPHX1 | |
| SCHEMBL18924835 | 0.96 | NAAA (0.50) | EPHX2ALDH1A1NAAAPPARGEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116023552-B | Catalyst and catalyst system for olefin polymerization | 中国石油化工股份有限公司 | 2024-12-06 | — | — | CN | claimed |
| CN-116023553-B | Catalyst component for olefin polymerization reaction, catalyst system and application | 中国石油化工股份有限公司 | 2024-09-17 | — | — | CN | claimed |
| CN-116023553-A | Catalyst for olefin polymerization reaction, catalyst system and application | 中国石油化工股份有限公司 | 2023-04-28 | — | — | CN | claimed |
| CN-116023552-A | Catalyst and catalyst system for olefin polymerization | 中国石油化工股份有限公司 | 2023-04-28 | — | — | CN | claimed |
| CN-116023554-A | Catalyst active component, solid catalyst and catalyst system for olefin polymerization | 中国石油化工股份有限公司 | 2023-04-28 | — | — | CN | claimed |
| CN-114174828-A | Biomarkers for irritable bowel syndrome | 利物浦大学 | 2022-03-11 | — | — | CN | claimed |
| US-20210228525-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | ARBOR PHARMACEUTICALS, LLC | 2021-07-29 | — | — | US | claimed |
| CN-105524192-B | Polypropylene catalyst composition with high temperature active inhibitory action and application thereof | 大唐国际化工技术研究院有限公司 | 2017-11-14 | — | — | CN | claimed |
| WO-2016182898-A1 | METHODS OF USE FOR MONOMETHYL FUMARATE AND PRODRUGS THEREOF | XENOPORT, INC. (US) | 2016-11-17 | — | — | WO | claimed |
| EP-2887934-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | XenoPort, Inc. (US) | 2015-07-01 | — | — | EP | claimed |
| WO-2014031844-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | XENOPORT, INC. (US) | 2014-02-27 | — | — | WO | claimed |
| US-20140057918-A1 | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof | XENOPORT, INC. (US) | 2014-02-27 | — | — | US | claimed |
| EP-2650279-A2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XenoPort, Inc. (US) | 2013-10-16 | — | — | EP | claimed |
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2012-06-21 | — | — | US | claimed |
| WO-2010022177-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | WO | claimed |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | US | claimed |
| CN-100569944-C | Production of polyketides and other natural products | BIOTICA TECH LTD (GB) | 2009-12-16 | — | — | CN | claimed |
| CN-101302550-A | Production of polyketides and other natural products | BIOTICA TECH LTD (GB) | 2008-11-12 | — | — | CN | claimed |
| CN-1668741-A | Production of polyketides and other natural products | BIOTICA TECH LTD (GB) | 2005-09-14 | — | — | CN | claimed |
| US-5665519-A | VERTICAL ORIENTING, CHEMICAL AMPLIFICATION TYPE, ACID CATALYST | NEC CORPORATION (JP) | 1997-09-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | EPHX2 608/4885ALDH1A1 2050/4885NAAA 774/4885 |
| US-20140057918-A1 | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof | FH, FAH, DHFR | EPHX2 708/4885ALDH1A1 1063/4885NAAA 730/4885 |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | EPHX2 608/4885ALDH1A1 2050/4885NAAA 774/4885 |
| US-20210228525-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | FH, FAH, ALDOA | EPHX2 973/4885ALDH1A1 626/4885NAAA 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.